Award of NHS Framework Agreement for Proprietary Pharmaceuticals Supply in North of England (Tranche B)

About

NHS England awarded a framework agreement to Astellas Pharma Ltd., Aventis Pharma Limited t/a Sanofi, Bayer Public Limited Company, Biogen Idec Limited, Boehringer Ingelheim Limited, Bristol-Myers Squibb Pharmaceuticals Limited, and Daiichi Sankyo UK Limited for the supply of proprietary pharmaceuticals to participating authorities in the NHS North of England region.

The framework period is 1 March 2018 to 29 February 2020, with an option to extend for up to 24 months at the Authority's discretion.

The framework is intended for use by the Department of Health and Social Care, Public Health England, and the NHS in England, and may also be used by private sector contractors and agents working on behalf of these bodies.

The advertised awarding value is £521.1 million over the full potential four-year period, with the initial two-year period carrying a value of £260.55 million (£130.275 million per annum).